Compare 8x8 Inc (EGHT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? 8x8 Inc trades at $2.13 (market cap $309.09M), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 434.3× 8x8 Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals.
| EGHT | VRTX | |
|---|---|---|
Market Cap | $309.09M | $134.25B |
Sector | Technology | Health |
52-Week High | $2.76 | $529.65 |
52-Week Low | $1.59 | $376.62 |
Enterprise Value | $576.02M | $128.37B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
